Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Top Cited Papers
- 1 December 2007
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 370 (9605), 2103-2111
- https://doi.org/10.1016/s0140-6736(07)61904-7
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell CancerJournal of Clinical Oncology, 2006
- Treatment for renal cancer: are we beyond the cytokine era?Nature Reviews Endocrinology, 2006
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?Nature Clinical Practice Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Bevacizumab for Patients with Metastatic Renal CancerClinical Cancer Research, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000